TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway

Xiao,Zhangxian; Xiao,Zhangxian; Li,Mingxi; Li,Mingxi; Zhang,Xiaoqian; Zhang,Xiaoqian; Rong,Xuezhu; Rong,Xuezhu; Xu,Hongtao; Xu,Hongtao

doi:10.3892/or.2023.8521

TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway

Authors:
- Zhangxian Xiao
- Mingxi Li
- Xiaoqian Zhang
- Xuezhu Rong
- Hongtao Xu
View Affiliations

Affiliations: Department of Pathology, The First Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning 110122, P.R. China, Department of Pathology, The First Hospital of China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China
Published online on: March 8, 2023 https://doi.org/10.3892/or.2023.8521
Article Number: 84
Copyright: © Xiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) accounts for the majority of lung cancers and remains the most common cause of cancer‑related death. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR‑TKIs) have been used as first‑line treatment for patients with NSCLC showing EGFR mutations. Unfortunately, drug resistance is a crucial barrier affecting the treatment of patients with NSCLC. Thyroid hormone receptor interactor 13 (TRIP13) is an ATPase that is overexpressed in numerous tumors and is involved in drug resistance. However, whether TRIP13 plays a role in regulating sensitivity to EGFR‑TKIs in NSCLC remains unknown. TRIP13 expression was evaluated in gefitinib‑sensitive (HCC827) and ‑resistant (HCC827GR and H1975) cell lines. The effect of TRIP13 on gefitinib sensitivity was assessed using the MTS assay. The expression of TRIP13 was upregulated or knocked down to determine its effect on cell growth, colony formation, apoptosis and autophagy. Additionally, the regulatory mechanism of TRIP13 on EGFR and its downstream pathways in NSCLC cells were examined using western blotting, immunofluorescence and co‑immunoprecipitation assays. The expression levels of TRIP13 were significantly higher in gefitinib‑resistant than in gefitinib‑sensitive NSCLC cells. TRIP13 upregulation enhanced cell proliferation and colony formation while reducing the apoptosis of gefitinib‑resistant NSCLC cells, suggesting that TRIP13 may facilitate gefitinib resistance in NSCLC cells. In addition, TRIP13 improved autophagy to desensitize gefitinib in NSCLC cells. Furthermore, TRIP13 interacted with EGFR and induced its phosphorylation and downstream pathways in NSCLC cells. The present study demonstrated that TRIP13 overexpression promotes gefitinib resistance in NSCLC by regulating autophagy and activating the EGFR signaling pathway. Thus, TRIP13 could be used as a biomarker and therapeutic target for gefitinib resistance in NSCLC.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
2	Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
3	Majem M and Remon J: Tumor heterogeneity: Evolution through space and time in EGFR mutant non small cell lung cancer patients. Transl Lung Cancer Res. 2:226–237. 2013.PubMed/NCBI
4	Westover D, Zugazagoitia J, Cho BC, Lovly CM and Paz-Ares L: Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29 (Suppl_1):i10–i19. 2018. View Article : Google Scholar : PubMed/NCBI
5	Clairmont CS, Sarangi P, Ponnienselvan K, Galli LD, Csete I, Moreau L, Adelmant G, Chowdhury D, Marto JA and D'Andrea AD: TRIP13 regulates DNA repair pathway choice through REV7 conformational change. Nat Cell Biol. 22:87–96. 2020. View Article : Google Scholar : PubMed/NCBI
6	Ma HT and Poon RY: TRIP13 functions in the establishment of the spindle assembly checkpoint by replenishing O-MAD2. Cell Rep. 22:1439–1450. 2018. View Article : Google Scholar : PubMed/NCBI
7	Ye Q, Kim DH, Dereli I, Rosenberg SC, Hagemann G, Herzog F, Tóth A, Cleveland DW and Corbett KD: The AAA+ ATPase TRIP13 remodels HORMA domains through N-terminal engagement and unfolding. EMBO J. 36:2419–2434. 2017. View Article : Google Scholar : PubMed/NCBI
8	Alfieri C, Chang L and Barford D: Mechanism for remodelling of the cell cycle checkpoint protein MAD2 by the ATPase TRIP13. Nature. 559:274–278. 2018. View Article : Google Scholar : PubMed/NCBI
9	Yost S, de Wolf B, Hanks S, Zachariou A, Marcozzi C, Clarke M, de Voer R, Etemad B, Uijttewaal E, Ramsay E, et al: Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation. Nat Genet. 49:1148–1151. 2017. View Article : Google Scholar : PubMed/NCBI
10	Raina VB and Vader G: Homeostatic control of meiotic prophase checkpoint function by Pch2 and Hop1. Curr Biol. 30:4413–4424.e5. 2020. View Article : Google Scholar : PubMed/NCBI
11	Li C, Xia J, Franqui-Machin R, Chen F, He Y, Ashby TC, Teng F, Xu H, Liu D, Gai D, et al: TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. J Clin Invest. 131:e1468932021. View Article : Google Scholar : PubMed/NCBI
12	Sheng N, Yan L, Wu K, You W, Gong J, Hu L, Tan G, Chen H and Wang Z: TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer. Cell Death Dis. 9:4022018. View Article : Google Scholar : PubMed/NCBI
13	Zhang G, Zhu Q, Fu G, Hou J, Hu X, Cao J, Peng W, Wang X, Chen F and Cui H: TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis. Br J Cancer. 121:1069–1078. 2019. View Article : Google Scholar : PubMed/NCBI
14	Zhou XY and Shu XM: TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through notch signaling pathway. Eur Rev Med Pharmacol Sci. 23:522–529. 2019.PubMed/NCBI
15	Dong L, Ding H, Li Y, Xue D, Li Z, Liu Y, Zhang T, Zhou J and Wang P: TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer. Int J Biol Macromol. 121:200–206. 2019. View Article : Google Scholar : PubMed/NCBI
16	Yu L, Xiao Y, Zhou X, Wang J, Chen S, Peng T and Zhu X: TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression. Biomed Pharmacother. 120:1095082019. View Article : Google Scholar : PubMed/NCBI
17	Cai W, Ni W, Jin Y and Li Y: TRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signaling. Cancer Biomark. 30:237–248. 2021. View Article : Google Scholar : PubMed/NCBI
18	Li W, Zhang G, Li X, Wang X, Li Q, Hong L, Shen Y, Zhao C, Gong X, Chen Y and Zhou J: Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma. Biochem Biophys Res Commun. 499:416–424. 2018. View Article : Google Scholar : PubMed/NCBI
19	Li ZH, Lei L, Fei LR, Huang WJ, Zheng YW, Yang MQ, Wang Z, Liu CC and Xu HT: TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition. J Mol Histol. 52:11–20. 2021. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Huang J, Li B, Xue H, Tricot G, Hu L, Xu Z, Sun X, Chang S, Gao L, et al: A small-molecule inhibitor targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 80:536–548. 2020. View Article : Google Scholar : PubMed/NCBI
21	Banerjee R, Liu M, Bellile E, Schmitd LB, Goto M, Hutchinson MN, Singh P, Zhang S, Damodaran DP, Nyati MK, et al: Phosphorylation of TRIP13 at Y56 induces radiation resistance but sensitizes head and neck cancer to cetuximab. Mol Ther. 30:468–484. 2022. View Article : Google Scholar : PubMed/NCBI
22	Lu S, Guo M, Fan Z, Chen Y, Shi X, Gu C and Yang Y: Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer. Am J Transl Res. 11:4397–4410. 2019.PubMed/NCBI
23	Levine B and Kroemer G: Biological functions of autophagy genes: A disease perspective. Cell. 176:11–42. 2019. View Article : Google Scholar : PubMed/NCBI
24	Galluzzi L and Green DR: Autophagy-independent functions of the autophagy machinery. Cell. 177:1682–1699. 2019. View Article : Google Scholar : PubMed/NCBI
25	Dikic I and Elazar Z: Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 19:349–364. 2018. View Article : Google Scholar : PubMed/NCBI
26	Wu M and Zhang P: EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Cancer Lett. 469:207–216. 2020. View Article : Google Scholar : PubMed/NCBI
27	Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
28	Amaravadi RK, Kimmelman AC and Debnath J: Targeting autophagy in cancer: Recent advances and future directions. Cancer Discov. 9:1167–81. 2019. View Article : Google Scholar : PubMed/NCBI
29	Sigismund S, Avanzato D and Lanzetti L: Emerging functions of the EGFR in cancer. Mol Oncol. 12:3–20. 2018. View Article : Google Scholar : PubMed/NCBI
30	Cheng WL, Feng PH, Lee KY, Chen KY, Sun WL, Van Hiep N, Luo CS and Wu SM: The role of EREG/EGFR pathway in tumor progression. Int J Mol Sci. 22:128282021. View Article : Google Scholar : PubMed/NCBI
31	Pao W and Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol. 23:2556–2568. 2005. View Article : Google Scholar : PubMed/NCBI
32	Liu Q, Yu S, Zhao W, Qin S, Chu Q and Wu K: EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 17:532018. View Article : Google Scholar : PubMed/NCBI
33	Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
34	Han W, Pan H, Chen Y, Sun J, Wang Y, Li J, Ge W, Feng L, Lin X, Wang X, et al: EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 6:e186912011. View Article : Google Scholar : PubMed/NCBI
35	Li YY, Lam SK, Mak JC, Zheng CY and Ho JC: Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer. 81:354–361. 2013. View Article : Google Scholar : PubMed/NCBI
36	Gremke N, Polo P, Dort A, Schneikert J, Elmshäuser S, Brehm C, Klingmüller U, Schmitt A, Reinhardt HC, Timofeev O, et al: mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. Nat Commun. 11:46842020. View Article : Google Scholar : PubMed/NCBI
37	Rong X, Liang Y, Han Q, Zhao Y, Jiang G, Zhang X, Lin X, Liu Y, Zhang Y, Han X, et al: Molecular mechanisms of tyrosine kinase inhibitor resistance induced by membranous/cytoplasmic/nuclear translocation of epidermal growth factor receptor. J Thorac Oncol. 14:1766–1783. 2019. View Article : Google Scholar : PubMed/NCBI